University of Maryland, Baltimore
770
112
152
415
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
19.1%
147 terminated/withdrawn out of 770 trials
73.8%
-12.7% vs industry average
13%
99 trials in Phase 3/4
56%
233 of 415 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (770)
Neural Correlates of Hypoalgesia Driven by Observation
Role: lead
Risk Factors, Costs, and Impacts of ED Boarding
Role: lead
Spironolactone for Pulmonary Arterial Hypertension
Role: collaborator
Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
Role: collaborator
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
Role: lead
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer
Role: lead
Comparing Direct vs Indirect Methods for Cascade Screening
Role: lead
Preserving Ability Through Virtual Exercise (PAVE)
Role: lead
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
Role: collaborator
Enhancing Care & Outcomes for Patients During the First Postpartum Year
Role: lead
The Volunteering-in-Place Program for Apathetic Assisted Living Residents With ADRD
Role: lead
Opioid Analgesic Reduction Study
Role: collaborator
Diaphragm Structure and Function in Childhood Cancer Survivors
Role: lead
Pre-Incision Peripheral Nerve Blocks for Lower Extremity Fracture Surgery in Older Adults
Role: lead
Diaphragm Structure and Function in Children
Role: lead
Diclofenac as a KMO Inhibitor
Role: lead
Assessment of Treatment Variability for Pelvic Ring Fragility Fractures
Role: lead
Blood Donor CVD 5000
Role: lead
Trial of Imatinib for Hospitalized Adults With COVID-19
Role: lead
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
Role: lead